[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.] #  @thecellengineer andrew andrew posts on X about $alt, alt, mash, ceo the most. They currently have XX followers and XX posts still getting attention that total XXX engagements in the last XX hours. ### Engagements: XXX [#](/creator/twitter::1455284275356520452/interactions)  - X Week XXXXX +268% - X Month XXXXX +239% ### Mentions: XX [#](/creator/twitter::1455284275356520452/posts_active)  - X Week XX +33% - X Month XX +221% ### Followers: XX [#](/creator/twitter::1455284275356520452/followers)  - X Week XX +3.20% - X Month XX +92% ### CreatorRank: XXXXXXXXX [#](/creator/twitter::1455284275356520452/influencer_rank)  ### Social Influence **Social topic influence** [$alt](/topic/$alt) #12, [alt](/topic/alt) #1057, [mash](/topic/mash) 8.33%, [ceo](/topic/ceo) 8.33%, [market cap](/topic/market-cap) #733, [strong](/topic/strong) 8.33%, [if you](/topic/if-you) 4.17%, [top performing](/topic/top-performing) 4.17%, [$2bn](/topic/$2bn) 4.17%, [$8bn](/topic/$8bn) XXXX% **Top accounts mentioned or mentioned by** [@merricklackner](/creator/undefined) [@brwtoovey](/creator/undefined) [@altnicholson](/creator/undefined) [@adirondackback](/creator/undefined) [@zacharybrennan](/creator/undefined) [@sanctuarybio](/creator/undefined) [@fumanchu6666](/creator/undefined) [@arianawatchlist](/creator/undefined) **Top assets mentioned** [AltLayer (ALT)](/topic/$alt) [Viking Therapeutics, Inc (VKTX)](/topic/$vktx) ### Top Social Posts Top posts by engagements in the last XX hours "As an AltImmune ($ALT) shareholder Id like to offer my X. *Sobering considerations* $ALT does have the best obesity asset from an M&A perspective. Yes pemvi *might* have better quality weight loss than some GLP-1s or Triple G" [X Link](https://x.com/thecellengineer/status/1996970096594768145) 2025-12-05T15:49Z XX followers, XXX engagements "$ALT is well capitalized to fund a Ph3 MASH study and Ph2 AUD/ALD studies - good negotiating leverage" [X Link](https://x.com/thecellengineer/status/1996970109945229772) 2025-12-05T15:49Z XX followers, XX engagements "@Sanctuary_Bio Not sure if you went into analyzing holdings but if so did you notice a power law effect for the top performing funds" [X Link](https://x.com/thecellengineer/status/1996353344898826415) 2025-12-03T22:58Z XX followers, XXX engagements "A phase X is necessary to prove it outright but MASH is a hot landscape and it is likely there is Pharma interested in partnering and acquiring $ALT. I estimate that to be in the $2Bn-$8Bn depending on timing and market dynamics but come to your own conclusions" [X Link](https://x.com/thecellengineer/status/1996970104412950839) 2025-12-05T15:49Z XX followers, XX engagements "New $ALT management CEO CMO CCO take commercial launch and bd skills to new heights. They seem poised and articulate on calls over the past month" [X Link](https://x.com/thecellengineer/status/1996970105918624220) 2025-12-05T15:49Z XX followers, XX engagements "@fumanchu6666 $ALT I like the setup too. Other than tolerability how the 48wk data could be bad highly unlikely we see an inversion of NITs given all the similar assets in MASLD and there are no biopsies to get hammered with. I think EOP FDA interaction is bigger catalyst - NIT approval = ✅" [X Link](https://x.com/thecellengineer/status/1996692312421027908) 2025-12-04T21:25Z XX followers, XXX engagements "@arianawatchlist Highly doubt $ALT leapfrogs $VKTX in market cap that soon but personally I would not mind that :)" [X Link](https://x.com/thecellengineer/status/1996694485519245477) 2025-12-04T21:33Z XX followers, XXX engagements "The obesity market I.e. payers pharma and to some degree (unaware) patients do not value quality of weight loss. That could shift into 26/27 but not as of now" [X Link](https://x.com/thecellengineer/status/1996970099685949728) 2025-12-05T15:49Z XX followers, XX engagements "Pemvi is competing for pole position in MASH and AUD/ALD for GLP-1/GCGR class but there are many other assets out there that could fast follow. Pemvi is not *that* unique. Just look at DD01" [X Link](https://x.com/thecellengineer/status/1996970101258748407) 2025-12-05T15:49Z XX followers, XX engagements "*Optimistic considerations* $ALT has a $550M market cap. Pemvi might be better in most regards that matter than FGF21 assets two of which were acquired earlier this year in the multi-billion range. The Ph2 48wk data about to drop will help prove this but the 24wk data is strong" [X Link](https://x.com/thecellengineer/status/1996970102852669512) 2025-12-05T15:49Z XX followers, XX engagements "The scientific community does appear open to support company claims of pemvidutide. Just look at AASLD and Lancet pub. Certainly not the only sexy new MASH drug but it is shiny" [X Link](https://x.com/thecellengineer/status/1996970108519116974) 2025-12-05T15:49Z XX followers, XX engagements "Incumbent CEO Jerry Durso seems to have fresh ideas to maximize shareholder value which he will disclose in Jan when he takes the reins" [X Link](https://x.com/thecellengineer/status/1996970111807234514) 2025-12-05T15:49Z XX followers, XX engagements "FDA input on whether they can use NIT in Ph3 will have a heavy impact on momentum going into 2026. Even if they still need biospies I see solid upside for the reason above but a NIT-only registrational MASH trial would be attractive for $ALT expenses and execution velocity" [X Link](https://x.com/thecellengineer/status/1996970115787571373) 2025-12-05T15:49Z XX followers, XX engagements "Weighing the sobering and optimistic considerations of $ALT and a good likelihood of positive 48wk data I see substantial upside in $ALT. But I also do not think it is the best metabolic company since sliced bread. It just has a solid setup for investors" [X Link](https://x.com/thecellengineer/status/1996970113933729945) 2025-12-05T15:49Z XX followers, XX engagements "All said I appreciate everyone on this platform who posts fact-based educational content about $ALT and pemvi but I was people wouldnt be so focused on comparison. These companies will either be acquired or not and there is likely room enough for many strong assets in Pharma" [X Link](https://x.com/thecellengineer/status/1996970117956260342) 2025-12-05T15:49Z XX followers, XXX engagements
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
@thecellengineer andrew
andrew posts on X about $alt, alt, mash, ceo the most. They currently have XX followers and XX posts still getting attention that total XXX engagements in the last XX hours.
Engagements: XXX #
- X Week XXXXX +268%
- X Month XXXXX +239%
Mentions: XX #
- X Week XX +33%
- X Month XX +221%
Followers: XX #
- X Week XX +3.20%
- X Month XX +92%
CreatorRank: XXXXXXXXX #
Social Influence
Social topic influence $alt #12, alt #1057, mash 8.33%, ceo 8.33%, market cap #733, strong 8.33%, if you 4.17%, top performing 4.17%, $2bn 4.17%, $8bn XXXX%
Top accounts mentioned or mentioned by @merricklackner @brwtoovey @altnicholson @adirondackback @zacharybrennan @sanctuarybio @fumanchu6666 @arianawatchlist
Top assets mentioned AltLayer (ALT) Viking Therapeutics, Inc (VKTX)
Top Social Posts
Top posts by engagements in the last XX hours
"As an AltImmune ($ALT) shareholder Id like to offer my X. Sobering considerations $ALT does have the best obesity asset from an M&A perspective. Yes pemvi might have better quality weight loss than some GLP-1s or Triple G"
X Link 2025-12-05T15:49Z XX followers, XXX engagements
"$ALT is well capitalized to fund a Ph3 MASH study and Ph2 AUD/ALD studies - good negotiating leverage"
X Link 2025-12-05T15:49Z XX followers, XX engagements
"@Sanctuary_Bio Not sure if you went into analyzing holdings but if so did you notice a power law effect for the top performing funds"
X Link 2025-12-03T22:58Z XX followers, XXX engagements
"A phase X is necessary to prove it outright but MASH is a hot landscape and it is likely there is Pharma interested in partnering and acquiring $ALT. I estimate that to be in the $2Bn-$8Bn depending on timing and market dynamics but come to your own conclusions"
X Link 2025-12-05T15:49Z XX followers, XX engagements
"New $ALT management CEO CMO CCO take commercial launch and bd skills to new heights. They seem poised and articulate on calls over the past month"
X Link 2025-12-05T15:49Z XX followers, XX engagements
"@fumanchu6666 $ALT I like the setup too. Other than tolerability how the 48wk data could be bad highly unlikely we see an inversion of NITs given all the similar assets in MASLD and there are no biopsies to get hammered with. I think EOP FDA interaction is bigger catalyst - NIT approval = ✅"
X Link 2025-12-04T21:25Z XX followers, XXX engagements
"@arianawatchlist Highly doubt $ALT leapfrogs $VKTX in market cap that soon but personally I would not mind that :)"
X Link 2025-12-04T21:33Z XX followers, XXX engagements
"The obesity market I.e. payers pharma and to some degree (unaware) patients do not value quality of weight loss. That could shift into 26/27 but not as of now"
X Link 2025-12-05T15:49Z XX followers, XX engagements
"Pemvi is competing for pole position in MASH and AUD/ALD for GLP-1/GCGR class but there are many other assets out there that could fast follow. Pemvi is not that unique. Just look at DD01"
X Link 2025-12-05T15:49Z XX followers, XX engagements
"Optimistic considerations $ALT has a $550M market cap. Pemvi might be better in most regards that matter than FGF21 assets two of which were acquired earlier this year in the multi-billion range. The Ph2 48wk data about to drop will help prove this but the 24wk data is strong"
X Link 2025-12-05T15:49Z XX followers, XX engagements
"The scientific community does appear open to support company claims of pemvidutide. Just look at AASLD and Lancet pub. Certainly not the only sexy new MASH drug but it is shiny"
X Link 2025-12-05T15:49Z XX followers, XX engagements
"Incumbent CEO Jerry Durso seems to have fresh ideas to maximize shareholder value which he will disclose in Jan when he takes the reins"
X Link 2025-12-05T15:49Z XX followers, XX engagements
"FDA input on whether they can use NIT in Ph3 will have a heavy impact on momentum going into 2026. Even if they still need biospies I see solid upside for the reason above but a NIT-only registrational MASH trial would be attractive for $ALT expenses and execution velocity"
X Link 2025-12-05T15:49Z XX followers, XX engagements
"Weighing the sobering and optimistic considerations of $ALT and a good likelihood of positive 48wk data I see substantial upside in $ALT. But I also do not think it is the best metabolic company since sliced bread. It just has a solid setup for investors"
X Link 2025-12-05T15:49Z XX followers, XX engagements
"All said I appreciate everyone on this platform who posts fact-based educational content about $ALT and pemvi but I was people wouldnt be so focused on comparison. These companies will either be acquired or not and there is likely room enough for many strong assets in Pharma"
X Link 2025-12-05T15:49Z XX followers, XXX engagements